CoChat

Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual

Open access
Seydoux, Emilie, Homad, Leah J., MacCamy, Anna J., Parks, K. Rachael, Hurlburt, Nicholas K., Jennewein, Madeleine F., Akins, Nicholas R., Stuart, Andrew B., Wan, Yu-Hsin, Feng, Junli, Nelson, Rachael E., Singh, Suruchi, Cohen, Kristen W., McElrath, M. Juliana, Englund, Janet A., Chu, Helen Y., Pancera, Marie, McGuire, Andrew T., Stamatatos, Leonidas · 2020 · bioRxiv (Cold Spring Harbor Laboratory)
PreprintCited by 64

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

B cells specific for the SARS-CoV-2 S envelope glycoprotein spike were isolated from a COVID-19-infected subject using a stabilized spike-derived ectodomain (S2P) twenty-one days post-infection. Forty-four S2P-specific monoclonal antibodies were generated, three of which bound to the receptor binding domain (RBD). The antibodies were minimally mutated from germline and were derived from different B cell lineages. Only two antibodies displayed neutralizing activity against SARS-CoV-2 pseudo-virus. The most potent antibody bound the RBD in a manner that prevented binding to the ACE2 receptor, while the other bound outside the RBD. Our study indicates that the majority of antibodies against the viral envelope spike that were generated during the first weeks of COVID-19 infection are non-neutralizing and target epitopes outside the RBD. Antibodies that disrupt the SARS-CoV-2 spike-ACE2 interaction can potently neutralize the virus without undergoing extensive maturation. Such antibodies have potential preventive/therapeutic potential and can serve as templates for vaccine-design. IN BRIEF: SARS-CoV-2 infection leads to expansion of diverse B cells clones against the viral spike glycoprotein (S). The antibodies bind S with high affinity despite being minimally mutated. Thus, the development of neutralizing antibody responses by vaccination will require the activation of certain naïve B cells without requiring extensive somatic mutation. Highlights: Analysis of early B cell response to SARS-CoV-2 spike protein Most antibodies target non-neutralizing epitopes Potent neutralizing mAb blocks the interaction of the S protein with ACE2 Neutralizing antibodies are minimally mutated

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1101/2020.05.12.091298

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 32

  1. 10.1093/nar/gkn316 · DOI · Paper page
  2. 2010, Potent and persistent antibody responses against the receptor-binding domain of SARS-CoV spike protein in recovered patients, Virology journal, 7, 299, 10.1186/1743-422X-7-299 · DOI · Paper page
  3. Charif D, a.L.J. (2007). SeqinR 1.0–2: a contributed package to the R Project for statistical computing devoted to biological sequences retrieval and analysis (New York: Springer Verlag). · DOI · Paper page
  4. 10.1126/science.1205669 · DOI · Paper page
  5. Crawford, K.H.D. , Eguia, R. , Dingens, A.S. , Loes, A.N. , Malone, K.D. , Wolf, C.R. , Chu, H.Y. , Tortorici, M.A. , Veesler, D. , Murphy, M. , et al. (2020). Protocol and reagents for pseudotyping lentiviral particles with SARS-CoV-2 Spike protein for neutralization assays. bioRxiv, 2020.2004.2020.051219. · DOI
  6. 10.1073/pnas.1525510113 · DOI · Paper page
  7. 2020, An interactive web-based dashboard to track COVID-19 in real time, The Lancet infectious diseases, 20, 533, 10.1016/S1473-3099(20)30120-1 · DOI · Paper page
  8. 10.1038/cr.2016.152 · DOI · Paper page
  9. 10.1016/j.cell.2020.02.052 · DOI · Paper page
  10. 10.1074/jbc.M603275200 · DOI · Paper page
  11. 2014, Potent neutralization of MERS-CoV by human neutralizing monoclonal antibodies to the viral spike glycoprotein, Science translational medicine, 6, 234
  12. 2018, Stabilized coronavirus spikes are resistant to conformational changes induced by receptor recognition or proteolysis, Scientific reports, 8, 15701, 10.1038/s41598-018-34171-7 · DOI · Paper page
  13. 10.1038/nature02145 · DOI · Paper page
  14. 10.1038/nature09385 · DOI · Paper page
  15. 10.1093/infdis/jiy311 · DOI · Paper page
  16. Okba, N.M.A. , Muller, M.A. , Li, W. , Wang, C. , GeurtsvanKessel, C.H. , Corman, V.M. , Lamers, M.M. , Sikkema, R.S. , de Bruin, E. , Chandler, F.D. , et al. (2020). Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease 2019 Patients. Emerging infectious diseases 26. · DOI · Paper page
  17. 2020, Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV, Nature communications, 11, 1620, 10.1038/s41467-020-15562-9 · DOI · Paper page
  18. 10.1074/jbc.M600697200 · DOI · Paper page
  19. 10.1016/j.immuni.2018.03.026 · DOI · Paper page
  20. 10.1371/journal.ppat.1007236 · DOI · Paper page
  21. 10.1038/s41586-019-0934-8 · DOI · Paper page
  22. 10.1073/pnas.0307140101 · DOI · Paper page
  23. 10.1016/j.jim.2007.09.017 · DOI · Paper page
  24. 10.1038/nm1080 · DOI · Paper page
  25. 2019, High-Quality Library Preparation for NGS-Based Immunoglobulin Germline Gene Inference and Repertoire Expression Analysis, Frontiers in immunology, 10, 660, 10.3389/fimmu.2019.00660 · DOI · Paper page
  26. 2020, Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein, Cell, 181, 281, 10.1016/j.cell.2020.02.058 · doi:10.1016/j.cell.2020.02.058 · Paper page
  27. 2020, A human monoclonal antibody blocking SARS-CoV-2 infection, Nature communications, 11, 2251, 10.1038/s41467-020-16256-y · DOI · Paper page
  28. 10.1126/science.abb2507 · DOI · Paper page
  29. 10.1128/JVI.00912-14 · DOI · Paper page
  30. 2015, Junctional and allele-specific residues are critical for MERS-CoV neutralization by an exceptionally potent germline-like antibody, Nature communications, 6, 8223, 10.1038/ncomms9223 · DOI · Paper page
  31. Yuan, M. , Wu, N.C. , Zhu, X. , Lee, C.D. , So, R.T.Y. , Lv, H. , Mok, C.K.P. , and Wilson, I.A. (2020). A highly conserved cryptic epitope in the receptor-binding domains of SARS-CoV-2 and SARS-CoV. Science. · DOI
  32. 2017, Cryo-EM structures of MERS-CoV and SARS-CoV spike glycoproteins reveal the dynamic receptor binding domains, Nature communications, 8, 15092, 10.1038/ncomms15092 · DOI · Paper page

Cited by

See all 64

Metadata

Authors
Seydoux, E., Homad, L. J., MacCamy, A. J., Parks, K. R., Hurlburt, N. K., Jennewein, M. F., Akins, N. R., Stuart, A. B., Wan, Y.-H., Feng, J., Nelson, R. E., Singh, S., Cohen, K. W., McElrath, M. J., Englund, J. A., Chu, H. Y., Pancera, M., McGuire, A. T., & Stamatatos, L.
Venue
bioRxiv (Cold Spring Harbor Laboratory)
Publisher
openRxiv
Published
2020-05-12
OpenAlex
W3025262235
Cited by
64
References
7
Type
posted content
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.